NCT02731807View on ClinicalTrials.gov

TA-65 Pharmacokinetic Study

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

February 28, 2017

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Dose A: TA-65 24mg, powder

DIETARY_SUPPLEMENT

Dose B: TA-65, 8mg, powder

DIETARY_SUPPLEMENT

Dose C: TA-65 3.2mg, capsule

DIETARY_SUPPLEMENT

Dose D: TA-65 8mg, capsule

DIETARY_SUPPLEMENT

Dose E: TA-65 32mg, capsule

Trial Locations (1)

10016

NYU Langone Medical Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02731807 - TA-65 Pharmacokinetic Study | Biotech Hunter | Biotech Hunter